Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 10
1998 10
1999 40
2000 24
2001 24
2002 44
2003 36
2004 42
2005 44
2006 58
2007 32
2008 36
2009 45
2010 35
2011 36
2012 35
2013 31
2014 42
2015 33
2016 33
2017 20
2018 16
2019 28
2020 29
2021 19
2022 24
2023 20
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

782 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier P, Roche N, Faisy C. Devillier P, et al. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. ...Desloratadine and fexofenadine do not impair cognitive …
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levo …
Fexofenadine.
Markham A, Wagstaff AJ. Markham A, et al. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. doi: 10.2165/00003495-199855020-00012. Drugs. 1998. PMID: 9506246 Review.
Other double-blind clinical trials showed that fexofenadine 40 to 240mg twice daily was significantly more effective than placebo. Fexofenadine 180 or 240mg once daily was significantly more effective than placebo in patients with chronic idiopathic urticaria. ...
Other double-blind clinical trials showed that fexofenadine 40 to 240mg twice daily was significantly more effective than placebo. …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in montel

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Lai X, Yao F, An Y, Li X, Yang XD. Lai X, et al. Molecules. 2023 Mar 11;28(6):2556. doi: 10.3390/molecules28062556. Molecules. 2023. PMID: 36985529 Free PMC article.
In this study, we constructed a novel nanotherapeutic agent (PDL1-NP-FEXO) for cancer immunotherapy by attaching PD-L1 aptamers to albumin nanoparticles that were loaded with H1-antihitamine fexofenadine (FEXO). ...Similar to free PD-L1 aptamer, PDL1-NP could …
In this study, we constructed a novel nanotherapeutic agent (PDL1-NP-FEXO) for cancer immunotherapy by attaching PD-L1 aptamers to al …
An update on the clinical pharmacokinetics of fexofenadine enantiomers.
Akamine Y, Miura M. Akamine Y, et al. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):429-434. doi: 10.1080/17425255.2018.1459565. Epub 2018 Apr 11. Expert Opin Drug Metab Toxicol. 2018. PMID: 29635947 Review.
Fexofenadine is administered as a racemic mixture of (R)- and (S)-enantiomers. The plasma concentrations of (R)-fexofenadine in humans are about 1.5-fold higher than those of the (S)-enantiomer. ...
Fexofenadine is administered as a racemic mixture of (R)- and (S)-enantiomers. The plasma concentrations of (R)-fexofenadine i
[Determinants of the stereoselective pharmacokinetics of fexofenadine].
Akamine Y. Akamine Y. Yakugaku Zasshi. 2015;135(3):473-81. doi: 10.1248/yakushi.14-00218. Yakugaku Zasshi. 2015. PMID: 25759055 Free article. Review. Japanese.
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in humans. Fexofenadine is administered clinically as a racemic mixture, and the plasma concentration of (R)-fexofenadine is about 1. …
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in huma …
Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M, Uno T. Miura M, et al. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. ...T …
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports t …
Cardiovascular safety of fexofenadine HCl.
Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Pratt CM, et al. Am J Cardiol. 1999 May 15;83(10):1451-4. doi: 10.1016/s0002-9149(99)00124-1. Am J Cardiol. 1999. PMID: 10335761 Review.
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 mg twice daily. Fexofenadine HCl doses up to 800 mg once daily or 690 mg twice daily for 28 days resulted in no dose-related increases …
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 m …
The systemic safety of fexofenadine HCl.
Mason J, Reynolds R, Rao N. Mason J, et al. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 171-3. doi: 10.1046/j.1365-2222.1999.0290s3163.x. Clin Exp Allergy. 1999. PMID: 10444232 Review.
Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. ...Fexofenadine is formulated and marketed as the hydrochloride salt. The recommended dose of fexofenadine HC1 is 120 mg daily for SAR (either as 120 mg once d
Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. ...Fexofenadine is formula
Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.
Andersson NW, Torp-Pedersen C, Andersen JT. Andersson NW, et al. JAMA Pediatr. 2020 Aug 1;174(8):e201316. doi: 10.1001/jamapediatrics.2020.1316. Epub 2020 Aug 3. JAMA Pediatr. 2020. PMID: 32478810 Free PMC article.
IMPORTANCE: Fexofenadine hydrochloride is a frequently used drug for treatment of allergic conditions during pregnancy, but the fetal safety of fexofenadine use has not been well studied. ...Sensitivity analyses of the primary outcomes, including the comparisons of …
IMPORTANCE: Fexofenadine hydrochloride is a frequently used drug for treatment of allergic conditions during pregnancy, but the fetal …
782 results